As risk markets surge, especially US stocks (but also corporate bonds), it's hard not to scratch your head and ask how long this can carry on? I have no idea, but I think the end might be near. In the meantime, I stick to my standard investment approach.

This article contains a summary of full-year 2024 performance of the indices and assets tracked by EMC, plus historical data, too.

I "guessed" at how markets would perform in 2024 last year at this time. Some I got right, some I got wrong, not different from the pros.

This is the update of my personal portfolio for the most recent quarter ended September 30, 2024. 

This is an update of my personal portfolio performance in 2Q2024 and 1H2024, good on the surface but worse than the indices would suggest.

The 2024 en primeur campaign for Bordeaux is just starting. But is fine wine really a good investment? I don't think so anymore.

This is an update about my personal portfolio during and at the end of 1Q2024. It also discusses performance which I consider disappointing.

This is the 3rd and final article focused on anti-obesity drugs. It looks at valuations of shares of the two giants in this biz, LLY & NVO.

Eli Lilly (LLY) and Novo Nordisk (NVO) have been large players for decades in the market for diabetes medications and are currently...